What is the difference between Datopotamab and DS-8201?

Datopotamab deruxtecan and DS-8201 (Trastuzumab deruxtecan) are both antibody-drug conjugates (ADCs), but they target different molecules. Dedabrotomab mainly targets the TROP2 antigen, which is a protein highly expressed on the surface of a variety of solid tumor cells, while DS-8201 targets the HER2 receptor and is mainly used for the treatment of HER2-positive tumors. The two combine their respective targets and release cytotoxic drugs to kill cancer cells, but the differences in targets make their applicable patient groups and treatment areas different.

In terms of indications, dabrotuzumab is mainly used to treat TROP2 positive breast cancer and non-small cell lung cancer, while DS-8201 is widely used in the treatment of HER2 positive breast cancer, gastric cancer and other cancers. DS-8201Due to its powerful anti-tumor effect and good clinical data, it has been approved for marketing in many countries around the world, while dabrotuzumab is currently actively advancing clinical trials and has demonstrated good therapeutic potential, especially in drug-resistant patients.

In terms of efficacy, DS-8201 has shown a high objective response rate and prolonged progression-free survival in HER2 positive breast cancer patients, making it an important treatment option in this field. Dedabrotuzumab has also shown good anti-tumor activity in clinical trials, especially in patients with tumors with high TROP2 expression, showing the potential to improve patient prognosis. The safety characteristics of the two are also different, and drug selection and management need to be based on the specific conditions of the patient.

From a research and development background, DS-8201 was jointly developed by Daiichi Sankyo and AstraZeneca and is a mature HER2 targetingADC drugs; and dedabrotuzumab, also developed by Daiichi Sankyo, relies on its advanced DXd coupling technology to provide new treatment options for more types of tumor patients. Generally speaking, although both belong to the same ADCSimilar drugs, but due to different targets and indications, each has its own advantages and positioning in clinical application.

Reference materials:https://www.drugs.com/